Biotech & Pharma Stocks
Leading biotechnology and pharmaceutical companies from GLP-1 obesity drug makers to CRISPR gene editing pioneers, mRNA therapeutics, and life sciences tools providers.
Need professional-grade screening and analysis? Visit stockanalysis.com
Sector:25 stocks
Sort:
| Name | Ticker | Sector/Focus | Market Cap | Country | Why Included |
|---|---|---|---|---|---|
| Eli Lilly | LLY.US | Big Pharma | $850B | US | GLP-1 (Mounjaro/Zepbound), oncology |
| Novo Nordisk | NVO.US | Big Pharma | $550B | Denmark | Ozempic, Wegovy, diabetes/obesity |
| Johnson & Johnson | JNJ.US | Big Pharma | $380B | US | Immunology, oncology, medtech |
| AbbVie | ABBV.US | Big Pharma | $340B | US | Humira, Skyrizi, Rinvoq |
| Merck | MRK.US | Big Pharma | $260B | US | Keytruda (oncology), vaccines |
| AstraZeneca | AZN.US | Big Pharma | $230B | UK | Oncology, respiratory, rare disease |
| Roche | ROG.SW | Big Pharma | $220B | Switzerland | Oncology, diagnostics |
| Thermo Fisher | TMO.US | Tools/CRO | $200B | US | Lab equipment, reagents, CRO |
| Amgen | AMGN.US | Large Biotech | $170B | US | Biosimilars, oncology, obesity (MariTide) |
| Danaher | DHR.US | Tools/CRO | $170B | US | Life sciences, diagnostics |
| Pfizer | PFE.US | Big Pharma | $140B | US | Vaccines, oncology, rare disease |
| Vertex Pharmaceuticals | VRTX.US | Large Biotech | $120B | US | Cystic fibrosis, pain, gene editing |
| Gilead Sciences | GILD.US | Large Biotech | $110B | US | HIV, HCV, oncology |
| Regeneron | REGN.US | Large Biotech | $90B | US | Dupixent, Eylea, oncology |
| Alnylam Pharmaceuticals | ALNY.US | Mid Biotech | $35B | US | RNAi therapeutics |
| Argenx | ARGX.US | Mid Biotech | $30B | Netherlands | Vyvgart, autoimmune |
| BioNTech | BNTX.US | Mid Biotech | $25B | Germany | mRNA oncology, vaccines |
| ICON plc | ICLR.US | Tools/CRO | $25B | Ireland | Contract research organization |
| Moderna | MRNA.US | Mid Biotech | $20B | US | mRNA vaccines and therapeutics |
| Illumina | ILMN.US | Tools/CRO | $20B | US | DNA sequencing platforms |
| Exact Sciences | EXAS.US | Specialty | $15B | US | Cancer screening (Cologuard) |
| BioMarin | BMRN.US | Specialty | $14B | US | Rare genetic diseases |
| Sarepta Therapeutics | SRPT.US | Specialty | $10B | US | Gene therapy, Duchenne |
| Charles River Labs | CRL.US | Tools/CRO | $10B | US | Preclinical CRO services |
| Intellia Therapeutics | NTLA.US | Mid Biotech | $3B | US | CRISPR gene editing |
Click column headers to sort · Market cap values are approximate · Click stock names to view detailed analysis
Disclaimer: This list is for informational purposes only and does not constitute investment advice. Market capitalizations are approximate and change frequently. Biotech stocks carry significant risks related to clinical trial outcomes, FDA approvals, and patent expirations. Always conduct your own research before making investment decisions.